CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response.
about
The Pharmacology of CD38/NADase: An Emerging Target in Cancer and Diseases of Aging.Daratumumab for the Treatment of Multiple Myeloma.CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of ResistanceStromal CD38 regulates outgrowth of primary melanoma and generation of spontaneous metastasisTargeting T Cell Metabolism for Improvement of Cancer Immunotherapy
P2860
CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response.
@en
CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response.
@nl
type
label
CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response.
@en
CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response.
@nl
prefLabel
CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response.
@en
CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response.
@nl
P2093
P2860
P50
P1433
P1476
CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response.
@en
P2093
Anusara Daenthanasanmak
Besim Ogretmen
Chrystal M Paulos
Craig C Beeson
Gyda Beeson
Hung Nguyen
Inhong Kang
Jeffery Rathmell
Jennifer Wu
Jinyu Zhang
P2860
P304
P356
10.1016/J.CMET.2017.10.006
P577
2017-11-09T00:00:00Z